CAPRICOR THERAPEUTICS, INC.
CAPRHeld by 4 specialist biotech funds
High Convergence4 funds opened new positions. Next phase2 readout (Deramiocel (CAP-1002)): Feb 2022. Short interest: 35.8% of float.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.